Therapeutic Asset Ratings
329 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Prevnar
Multiple Myeloma
Massachusetts General Hospital
P2
CCC
(48)
C-Car088
Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Melphalan Flufenamide
Plasma Cell Myeloma
Fondazione EMN Italy Onlus
P3
CC
(47)
Anti-Bcma-Car-T
Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
P2
CC
(46)
Auto Car T Cell Therapy
Plasma Cell Myeloma
Autolus Limited
P2
CC
(46)
Axitinib
Plasma Cell Myeloma
Canadian Cancer Trials Group
P2
CC
(46)
Budesonide
Plasma Cell Myeloma
University of Utah
P2
CC
(46)
Capivasertib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
Cellprotect
Plasma Cell Myeloma
Karolinska Institutet
P2
CC
(46)
Copanlisib
Plasma Cell Myeloma
OHSU Knight Cancer Institute
P2
CC
(46)
Defactinib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
Degarelix
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P2
CC
(46)
Elranatamab-Bcmm
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P2
CC
(46)
Emapalumab
Plasma Cell Myeloma
NYU Langone Health
P2
CC
(46)
Fam-Trastuzumab Deruxtecan-Nxki
Plasma Cell Myeloma
American Society of Clinical Oncology
P2
CC
(46)
Fluciclovine
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
Gdc-0068
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa
Plasma Cell Myeloma
Barbara Ann Karmanos Cancer Institute
P2
CC
(46)
Igpro20
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P2
CC
(46)
Larotrectinib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
LEUPROLIDE
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P2
CC
(46)
Mecapegfilgrastim
Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
P2
CC
(46)
Mit-001
Plasma Cell Myeloma
MitoImmune Therapeutics
P2
CC
(46)
Npi-2358
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P2
CC
(46)
Obinutuzumab
Multiple Myeloma
Janssen Research & Development, LLC
P2
CC
(46)
Showing 151 to 175 of 329 assets
Previous
Page 7 of 14
Next
